Happy Thanksgiving from Enliven Therapeutics!?
Enliven Therapeutics
生物技术研究
Discovering and developing next generation precision oncology therapeutics
关于我们
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.
- 网站
-
https://www.enliventherapeutics.com
Enliven Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boulder, CO
- 类型
- 私人持股
- 创立
- 2019
- 领域
- Precision Medicine、Small Molecule Targeted Therapies和Oncology
地点
-
主要
获取路线
US，Boulder, CO
Enliven Therapeutics员工
动态
-
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update:?https://bit.ly/3YQAHUq
-
-
Today we honor all those who have served and thank them for their courage and bravery. #VeteransDay
-
-
We look forward to participating in the Jefferies London Healthcare Conference later this month. Read today’s release for more details regarding our upcoming presentation:?https://bit.ly/4eo6ulv
-
-
#DYK: Recently released data from the ELVN-001 Phase 1 trial in heavily pre-treated patients with #CML demonstrated a cumulative MMR rate of 44% (8/18) by 24 weeks. This compares favorably to precedent Phase 1 cumulative MMRs for approved BCR::ABL TKIs https://bit.ly/3ZEyLQX
-
-
In our 2Q press release, we announced the first person was dosed in the Ph1a trial of ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in people with HER2+ MBC and CRC. We’re striving to improve on available treatments for #breastcancer: https://bit.ly/3xleJ21
-
-
There are no cures for #metastaticbreastcancer but research advancements have improved the outlook for people living with this disease. We are developing ELVN-002 with the goal of helping people with HER2+ mBC and other HER2+ cancers: https://bit.ly/3xleJ21
-
-
Today a positive data update from the Phase 1 clincal?trial of ELVN-001 was presented at the ESH-iCMLf Annual John Goldman Conference. Learn more about the updated data here: https://bit.ly/3ZEyLQX
-
-
Research is the foundation of progress in the fight against cancer. We hope our research can help fill the significant need for better treatment options for people living with CML and HER2+ cancers. Learn more here: https://bit.ly/3xleJ21 #WorldCancerResearchDay?
-